Ambrisentan News
Ambrisentan currently has 3 news articles, with 10 predicted indications.
This page combines the AI-predicted indications for Ambrisentan with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1)....
- Evidence level: L5
- Predicted indications (10):
- pulmonary arteriovenous malformation (disease) (99.4%)
- pulmonary arterial hypertension associated with congenital heart disease (99.4%)
- pulmonary arterial hypertension associated with chronic hemolytic anemia (99.3%)
- pulmonary arterial hypertension associated with HIV infection (99.3%)
- pulmonary arterial hypertension associated with connective tissue disease (99.3%)
- pulmonary arterial hypertension associated with schistosomiasis (99.3%)
- malformation syndrome with odontal and/or periodontal component (99.2%)
- hypotrichosis simplex of the scalp (99.2%)
- hypertrichosis (disease) (99.1%)
- syndrome with a Dandy-Walker malformation as major feature (99.1%)
Related News (3)
En prescrivant dès 1979 un comprimé contre l’hypertension sévère, le laboratoire Upjohn a littéralement ouvert un marché qu’aucun cardiologue n’avait imaginé
2026-10-09 hypertension
Source: Sciencepost
WHO stellt globale Roadmap gegen Bluthochdruckerkrankungen in der Schwangerschaft vor - Deutsches Ärzteblatt
2026-10-08 Bluthochdruck AF
Source: Deutsches Ärzteblatt
The generation raised on sugar rations – and what their health reveals 70 years later - The Guardian
2026-10-07 diabetes high blood pressure
Source: The Guardian
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.